Dr Tony Hunter

Salk Institute for Biological Studies | Professor, Molecular and Cell Biology Laboratory

Renato Dulbecco Chair in Cancer Research; American Cancer Society Professor

Tony Hunter received his BA and PhD from the University of Cambridge, England, and completed postdoctoral training at the Salk Institute for Biological Studies and the University of Cambridge. In 1979, through his work on tumor viruses as a faculty member at the Salk Institute, he discovered a new class of protein kinases that phosphorylate tyrosine residues in proteins, and demonstrated that dysregulated tyrosine phosphorylation by an activated tyrosine kinase causes malignant transformation. Subsequently, he and others showed that tyrosine phosphorylation is a widespread reversible protein modification essential for the regulation of a wide variety of cellular processes in multicellular eukaryotes, including transmembrane signal transduction by surface receptors, cell growth control, cell migration, axonal guidance and neural transmission, and cell cycle control. His work together with that of many others has shown that aberrant tyrosine phosphorylation is causal in several types of human cancer and in other diseases, and this has led to the successful development of inhibitors that target disease-causing tyrosine kinases (TKIs), such as Gleevec, a BCR-ABL inhibitor used for treatment of chronic myelogenous leukemia. Currently, 54 TKIs are approved for clinical use in the treatment of cancer and other diseases.

Hunter has spent much of the past 40 years studying protein kinases and phosphatases, and the role of protein phosphorylation in cell proliferation and the cell cycle, and how aberrant phosphorylation causes cancer. His group also works on other types of post-translational modiﬁcations (PTMs), including ubiquitylation, where he discovered the RING domain class of E3 Ub ligases, and sumoylation, where he identified a class of E3 ubiquitin ligases, STUbLs, that specifically target sumoylated proteins for ubiquitylation. Most recently, he has been studying histidine phosphorylation, and has generated monoclonal antibodies specific for the two isoforms of phosphohistidine, and used these to uncover a role for histidine phosphorylation in liver cancer. Most recently, he has investigated the role of stromal cells in pancreatic cancer, discovering a role for the LIF cytokine secreted by cancer-associated fibroblasts in tumor progression.

Hunter has received many awards for his work on tyrosine phosphorylation, including a Gairdner Canada International Award, the Louisa Gross Horwitz Prize, the Wolf Prize in Medicine, the Royal Medal of the Royal Society, and most recently the Pezcoller-AACR Award for Cancer Research, the Sjöberg Prize for Cancer Research and the Tang Prize for Biopharmaceutical Science. He is a Fellow of the Royal Society of London and the American Association for Cancer Research Academy, and a Member of the US National Academy of Sciences, the European Molecular Biology Organization, the American Academy of Arts and Sciences, the US National Academy of Medicine, and the American Philosophical Society.

New Signal Transduction Targets for Cancer Therapy

Tyrosine phosphorylation of proteins was discovered over 40 years ago, and in the interim its fundamental importance in many human diseases, including cancer, has been revealed. Tyrosine kinases have proved to be viable cancer drug targets, and, to date, 54 tyrosine kinase inhibitors (TKIs) have been approved for clinical use, mostly as cancer therapeutics.

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with few treatment options. Using mass spectrometry (MS) approaches, we have identified leukemia inhibitory factor (LIF), a stem cell factor, as a key paracrine factor, secreted mainly by activated cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), that acts on pancreatic tumor cells to stimulate JAK tyrosine kinase-mediated STAT3 tyrosine phosphorylation, which drives a gene expression program that maintains a stem cell-like population of tumor cells. Blockade of LIF with a neutralizing monoclonal antibody (mAb) slows tumor progression in the KPC mouse model of PDAC and augments the efficacy of gemcitabine chemotherapy treatment to prolong survival. LIF levels are strongly elevated in both mouse and human pancreatic tumor tissue, and LIF is also detected in serum from tumor-bearing mice and human PDAC patients, suggesting its use as both as a biomarker and as a therapeutic target. In addition, to its action on tumor cells, we have found that LIF acts on myeloid cells in the immune microenvironment to sustain a protumorigenic population of tumor-associated macrophages.

Histidine phosphorylation, the so-called “hidden phosphoproteome”, is poorly characterized. To study histidine phosphorylation we generated mAbs that selectively recognize the 1-pHis and 3-pHis isoforms, and have determined the structural basis of selective antibody recognition of 1-pHis and 3-pHis in proteins. We have used these mAbs for immunoblotting and immunofluorescence staining to detect increased levels of pHis proteins in human cell lines, and also to survey the pHis proteome, and, using MS, to identify new sites of histidine phosphorylation. Using these mAbs, we collaborated with Michael Hall (Biozentrum, Basel) to show that pHis levels are elevated in liver tumors both in a mouse model and in human hepatocellular carcinoma (HCC) tumor tissue, as a result of reduced levels of the LHPP pHis phosphatase in tumor tissue. On this basis, we propose that LHPP serves as a tumor suppressor in HCC, and that histidine phosphorylation can act as a cancer driver. Consistently, we have recently observed elevated levels of pHis proteins in pediatric neuroblastoma and PDAC stromal cells.